Imagine a tiny electronic device that can stop severe headaches, but instead of needing a major operation to put it in, it's delivered via a simple injection. It's like a wireless pacemaker for your nerves, controlled by a smartphone app and powered by a wearable device. This makes a high-tech treatment available to people who can't access specialized surgical centers.
Chronic migraine affects up to 2% of the population, but effective neurostimulation is limited by the need for invasive surgery and specialized surgeons, leaving many patients underserved.
A four-part platform: an implantable stimulator (LUNA-AIR), a wireless power wearable (LUNA-CONTROL), a control app (LUNA-APP), and a minimally invasive injection tool (LUNA-INJECT).
If you are a device manufacturer dealing with high surgical revision rates in occipital nerve stimulators — this project developed a minimally invasive injectable system that reduces tissue trauma and surgical risk.
If you are a software provider dealing with the lack of patient-controlled interfaces for implants — this project developed the LUNA-APP to control an implantable device via a mobile interface.
If you are a clinic operator dealing with a lack of surgically trained physicians — this project developed a delivery system that enables non-surgical physicians to treat chronic migraine patients.
Based on available project data, it reduces costs by replacing invasive surgery with a minimally invasive injection, allowing non-surgical physicians to perform the procedure.
Based on available project data, the project has completed the design, fabrication, and testing of the ASIC chip and delivery system, but large-scale industrial manufacturing details are not provided.
Based on available project data, the project has developed four specific components (LUNA-AIR, CONTROL, APP, and INJECT), but specific licensing terms are not mentioned.
The project period runs from 2022-09-01 to 2026-02-28, with the first two years focused on hardware and software characterization.
It integrates via a mobile app for control and a wearable device for wireless power, shifting the care pathway from surgical theaters to standard physician offices.
The consortium is highly commercially oriented with a 50% industry ratio, comprising 5 industrial partners (all SMEs) and 3 research organizations. This balance suggests a strong focus on productization rather than pure theory, with the University of Pisa coordinating a diverse group across 7 countries.
Contact the Università di Pisa regarding the LUNA platform licensing
Request a detailed technical briefing on the LUNA-INJECT delivery system.
